Linco-Spectin Injection 100ml
Spectinomycin sulfate tetrahydrate (equiv. spectinomycin base 100 mg/mL).
This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
We apologise that we are unable to display a photograph of the packaging or provide you with more information regarding this prescription medicine. Australian legislation prohibits the advertisement of prescription drugs to consumers.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Lincomycin hydrochloride monohydrate (equiv. lincomycin base 50 mg/mL) & Spectinomycin sulfate tetrahydrate (equiv. spectinomycin base 100 mg/mL).|
|Indication||Infections due to susceptible organisms in swine, broiler chickens, dogs and cats. Swine. Treatment and control of swine dysentery (Brachyspira hyodysenteriae) and enteritis associated with Escherichia coli. Aids in the control of mycoplasmal pneumonia. Broiler chickens. Chronic respiratory disease associated with Mycoplasma gallisepticum and E. coli. Dogs. Respiratory, skin and urinary tract infections, and secondary bacterial infections associated with viral diseases. Cats. Urinary tract and upper respiratory tract infections, localised infections and secondary bacterial infections associated with viral diseases.|
|Contraindications||Hypersensitivity to either antibiotic or the combination.|
|Actions||Microbiology Lincomycin. Produced by Streptomyces lincolnensis; in vitro studies have shown that the spectrum of activity is primarily against Gram-positive organisms, including Staphylococcus aureus, Staph. albus, β-haemolytic Streptococci, Streptococcus viridans, Clostridium tetani and Cl. perfringens. Lincomycin is not active against Strep. faecalis, Gram-negative bacteria, yeasts or fungi. It has shown in vitro activity against certain strains of Mycoplasma, spirochaetes and anaerobic organisms. In vivo studies have demonstrated activity against Strep. viridans, β-haemolytic Streptococci, Staph. aureus and Leptospira pomona. It is ineffective in Klebsiella, Pasteurella, Pseudomonas and Salmonella infections. Clinically, it has proved effective in upper respiratory tract infections, septicaemia, and in infections of the skin and adjoining tissues.Lincomycin has not shown cross resistance with penicillin, triacetyloleandomycin, chloramphenicol, novobiocin, streptomycin or the tetracyclines. Staphylococci develop resistance to lincomycin in a slow, step-wise manner as shown in in vitro serial subculture experiments. Spectinomycin. Produced by Streptomyces flavopersicus; in vitro it demonstrates activity against a variety of Gram-positive, Gram-negative and mycoplasmal organisms. It is primarily bacteriostatic in nature. Spectinomycin is effective in vivo against infections caused by Escherichia, Salmonella, Staphylococcus, Streptococcus and certain mycoplasmal organisms; parenteral administration is most effective against systemic infections.Although resistance development of organisms to spectinomycin has been demonstrated in vitro (serial passage under laboratory conditions) and in vivo (susceptibility testing of field isolates), significant resistance problems have not been reported.Pharmacokinetics Following intramuscular injection to dogs, peak levels of both antibiotics were obtained in one hour. At doses of spectinomycin 15 mg and lincomycin 7.5 mg/kg, the peak serum level for spectinomycin was 42 microgram/mL and for lincomycin 4.5 microgram/mL; these levels are in excess of the minimum inhibitory concentrations of the two antibiotics for many bacteria.Studies indicate that bile is an important route of excretion of lincomycin. Significant levels of lincomycin have been demonstrated in the majority of body tissues. After a single oral administration of lincomycin sterile solution to a dog, faecal excretion amounted to 77% of the dose; urinary excretion to 14%. After a single intramuscular injection, faecal excretion equalled 38% of the dose; and urinary excretion, 49%. Urinary excretion was essentially complete in less than 24 hours and faecal excretion by 48 hours after administration by either route. Lincomycin has also been shown to be excreted in the milk of lactating cows, goats, rats and humans. Following intramuscular administration, spectinomycin is rapidly excreted in the urine.|
|Precautions||Use in species other than those indicated may result in adverse gastrointestinal effects.|
|Dosage and Administration||Clean and disinfect the vial seal prior to withdrawing the dose with a sterile needle and syringe. Swine. 15 mg combined antibiotic activity/kg bodyweight (1 mL/10 kg) intramuscularly; repeat at 24 hour intervals for three to seven days as needed. Broiler chickens. 30 mg combined antibiotic activity/kg bodyweight (1 mL/5 kg) subcutaneously once daily for three consecutive days or inject once and follow with Linco-Spectin Soluble Powder water medication for three to five days. Dogs, cats. 30 mg combined antibiotic activity/kg bodyweight (1 mL/5 kg) intramuscularly; repeat at twelve to 24 hour intervals for up to 21 days if necessary.|
|Storage||Store below 30°C (room temperature).|
|MSDS (external link)||Linco-Spectin Injection 100ml MSDS|
|Label (external link)||Linco-Spectin Injection 100ml Label|
|Manufacturer||Zoetis Australia Pty Ltd|